Lentitek
Company Details
Status: Private
Employees: 1-10
Location:
Edinburgh, Scotland, United Kingdom
Type:
sample
Technology:
sample
sample
sample
About: Based in Edinburgh, Scotland. Lentitek has pioneered the development of alternative approaches to lentiviral vector production based on novel promoter technology conceived by Dr Adam Inche. The Lentitek platform was developed to address key issues limiting progression of ATMP assets and is now enabling the use of retrovirus based vectors in new and previously unviable applications.
Unique properties of the Lentitek platform can be leveraged to enable in-vivo CAR-T and armoured CAR applications in addition to addressing quality and yield inconsistencies within ex-vivo CAR-T manufacture.
The Lentitek platform is accessed through a serviced CRO license model where Lentiteks’ renowned team of vector design specialists work with asset developers to integrate the Ltek solution and validate performance including transfer to chosen manufacturing partner.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Lentitek | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.